Drugs / Frondanol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05194007 | Feb 2022 → Nov 2024 | Crohn's colitis, ulcerative colitis | Mohammed Bin Rashid University of Medicine and Health Sciences | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Frondanol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05194007 ↗ |
| Action | Inhibit | “likely mediated by the inhibition of 5-lipoxygenase and 12-lipoxygenase pathways” PMID 36544548 ↗ Dec 2022 |
| Route | Oral | “Frondanol capsule (1000 mg) will be administered orally (Twice daily) in the double blind settings” NCT05194007 ↗ |